Compositions and methods to create a vascularized environment for cellular transplantation

• US 20070122448A1
• Filed: 11/28/2005
• Published: 05/31/2007
• Est. Priority Date: 11/28/2005
• Status: Abandoned Application

• Current Assignee: Alireza Rezania, Jean Xu, Ragae Ghabrial
• Original Assignee: Alireza Rezania, Jean Xu, Ragae Ghabrial
• Inventors: Xu, Jean, Rezania, Alireza, Ghabrial, Ragae
• Application Number:
  US11/287,933
• Publication Number:
  US 20070122448A1
• Time in Patent Office: Days
• US Class Current: 424/426
• CPC Class Codes: A61K 31/235 having an aromatic ring attached to a carboxyl group
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof

Abstract

The present invention generally relates to biocompatible devices suitable for increasing cellular HIF-1 α protein levels. In particular, the present invention relates to an implant comprising a biocompatible support loaded with at least one pharmaceutical agent capable of increasing cellular HIF-1 α protein levels to promote vascularization at or near the implant site. Vascularization of the implanted support results in enhanced survival of cells optionally incorporated within the support. Methods for treating a disease or injury via implanting the support of the present invention are also provided.

Claims

1. A biocompatible implant, comprising a support and at least one pharmaceutical agent that increases cellular HIF-1α

protein levels.

2. The implant of claim 1, wherein the support is biodegradable.

5. The implant of claims 1 and 2, wherein the at least one pharmaceutical agent that increases cellular HIF-1α

protein levels is a HIF-1α

hydroxylase inhibitor.

6. The implant of claim 5, wherein the HIF-1α

hydroxylase inhibitor is selected from 2,4-diethylpyridinedicarboxylate and ethyl-3,4-dihydroxybenzoate.

7. The implant of claims 1 and 2, wherein the at least one pharmaceutical agent that is capable of increasing cellular HIF-1α

protein levels is incorporated into the support prior to the formation of the support by adding the at least one pharmaceutical agent into a polymer solution for forming the support.

8. The implant of claims 1 and 2, wherein the at least one pharmaceutical agent that is capable of increasing cellular HIF-1α

protein is incorporated into the support after the formation of the support by coating the support with the at least one pharmaceutical agent.

13. The implant of claims 1 and 2, further comprising mammalian tissue attached to, or incorporated within the support.

14. The implant of claim 13, wherein the mammalian tissue comprises cells, tissue isolated from an organ, or isolated organs.

33. The implant of claims 1 and 2, wherein the support is selected from the group consisting of a foam, or a fibrous mat encapsulated by and disposed within a foam.

35. The implant of claim 2, wherein the support is made of one or more biodegradable polymers.

36. The implant of claim 35, wherein the polymers are selected from the group consisting of hyaluronic acid, collagen, recombinant collagen, cellulose, elastin, alginates, chondroitin sulfate, chitosan, chitin, keratin, silk, small intestine submucosa (SIS), or combinations thereof.

37. The implant of claim 2, wherein the support is made from one or more synthetic polymers.

38. The implant of claim 37, wherein the polymers are selected from the group consisting of aliphatic polyesters, polyalkylene oxalates, polyamides, polycarbonates, polyorthoesters, polyoxaesters, polyamidoesters, polyanhydrides, and polyphosphazenes.

39. The implant of claim 38, wherein the polymers are aliphatic polyesters which are homopolymers or copolymers of monomers selected from the group consisting of lactic acid, lactide, glycolic acid, glycolide, ε

-caprolactone, p-dioxanone, trimethylene carbonate, polyoxaesters, δ

-valerolactone, β

-butyrolactone, ε

-decalactone, 2,5-diketomorpholine, pivalolactone, α

,α

-diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, γ

-butyrolactone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl-dioxepan-2-one and 6,8-dioxabicycloctane-7-one.

40. The implant of claim 37, wherein the polymers are elastomers.

41. The implant of claim 40, wherein the elastomers are selected from the group of copolymers consisting of ε

-caprolactone and glycolide, ε

-caprolactone and lactide, lactide and glycolide, p-dioxanone and lactide, ε

-caprolactone and p-dioxanone, p-dioxanone and trimethylene carbonate, trimethylene carbonate and glycolide, trimethylene carbonate and lactide, or combinations thereof.

42. The implant of claim 37, wherein the material comprising the support has a gradient structure, characterized by a continuous transition from a first biodegradable polymer composition to a second biodegradable polymer composition.

51. The implant of claim 33, wherein the fibrous mat of the support is made by a wet-lay or dry-lay procedure.

52. The implant of claim 33, wherein the foam of the support is formed by a polymer-solvent phase separation technique, supercritical solvent foaming, gas injection extrusion, gas injection molding, or casting with an extractable material.

3. A biocompatible implant, comprising a support and at least one pharmaceutical agent that inhibits the degradation of HIF-1α

protein.

4. The implant of claim 3, wherein the support is biodegradable.

9. The implant of claims 3 and 4, wherein the at least one pharmaceutical agent that inhibits the degradation of HIF-1α

protein is a HIF-1α

hydroxylase inhibitor.

10. The implant of claim 9, wherein the HIF-1α

hydroxylase inhibitor is selected from 2,4-diethylpyridinedicarboxylate and ethyl-3,4-dihydroxybenzoate.

11. The implant of claims 3 and 4, wherein the at least one pharmaceutical agent that inhibits the degradation of HIF-1α

protein is incorporated into the support prior to the formation of the support by adding the at least one pharmaceutical agent into a polymer solution for forming the support.

12. The implant of claims 3 and 4, wherein the at least one pharmaceutical agent that inhibits the degradation of HIF-1α

protein is incorporated into the support after the formation of the support by coating the support with the at least one pharmaceutical agent.

15. The implant of claims 3 and 4, further comprising mammalian tissue attached to, or incorporated within the support.

16. The implant of claim 15, wherein the mammalian tissue is cells, tissue isolated from an organ, or isolated organs.

34. The implant of claims 3 and 4, wherein the support is selected from the group consisting of a foam or a fibrous mat encapsulated by and disposed within a foam.

43. The implant of claim 4, wherein the support is made of one or more biodegradable polymers.

44. The implant of claim 43, wherein the polymers are selected from the group consisting of hyaluronic acid, collagen, recombinant collagen, cellulose, elastin, alginates, chondroitin sulfate, chitosan, chitin, keratin, silk, small intestine submucosa (SIS), or combinations thereof.

45. The implant of claim 4, wherein the support is made from one or more synthetic polymers.

46. The implant of claim 45, wherein the polymers are selected from the group consisting of aliphatic polyesters, polyalkylene oxalates, polyamides, polycarbonates, polyorthoesters, polyoxaesters, polyamidoesters, polyanhydrides, and polyphosphazenes.

47. The implant of claim 46, wherein the polymers are aliphatic polyesters which are homopolymers or copolymers of monomers selected from the group consisting of lactic acid, lactide, glycolic acid, glycolide, ε

-caprolactone, p-dioxanone, trimethylene carbonate, polyoxaesters, δ

-valerolactone, β

-butyrolactone, ε

-decalactone, 2,5-diketomorpholine, pivalolactone, α

,α

-diethylpropiolactone, ethylene carbonate, ethylene oxalate, 3-methyl-1,4-dioxane-2,5-dione, 3,3-diethyl-1,4-dioxan-2,5-dione, γ

-butyrolactone, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, 6,6-dimethyl-dioxepan-2-one and 6,8-dioxabicycloctane-7-one.

48. The implant of claim 45, wherein the polymers are elastomers.

49. The implant of claim 48, wherein the elastomers are selected from the group of copolymers consisting of ε

-caprolactone and glycolide, ε

-caprolactone and lactide, lactide and glycolide, p-dioxanone and lactide, ε

-caprolactone and p-dioxanone, p-dioxanone and trimethylene carbonate, trimethylene carbonate and glycolide, trimethylene carbonate and lactide, or combinations thereof.

50. The implant of claim 45, wherein the material comprising the support has a gradient structure, characterized by a continuous transition from a first biodegradable polymer composition to a second biodegradable polymer composition.

53. The implant of claim 34, wherein the fibrous mat of the support is made by a wet-lay or dry-lay procedure.

54. The implant of claim 34, wherein the foam of the support is formed by a polymer-solvent phase separation technique, supercritical solvent foaming, gas injection extrusion, gas injection molding, or casting with an extractable material.

17. A method of making a biocompatible implant to increase cellular HIF-1α

levels, comprising the steps of;

a. incorporating at least one pharmaceutical agent capable of increasing cellular HIF-1α

protein levels into a support;

b. isolating and preparing mammalian tissue, and

c. introducing the mammalian tissue into the support.

18. The method of claim 17, wherein the support is further treated with at least one pharmaceutical compound that is selected from the group consisting of a growth factor, an anti-rejection agent, an analgesic, an anti-oxidant, an anti-apoptotic agent, an anti-inflammatory agent, and an immunosuppressive drug.

19. A method of making a biocompatible implant to decrease the degradation of HIF-1α

protein, comprising the steps of;

a. incorporating at least one pharmaceutical agent capable of decreasing the degradation of HIF-1α

protein into a support;

b. isolating and preparing mammalian tissue, and

c. introducing the mammalian tissue into the support.

20. The method of claim 19, wherein the support is further treated with at least one pharmaceutical compound that is selected from the group consisting of a growth factor, an anti-apoptotic compound, an anti-inflammatory compound, and an immunosuppressive compound.

21. A method of promoting vascularization in a patient, comprising the steps of:

a. incorporating at least one pharmaceutical agent capable of increasing cellular HIF-1α

protein levels, and

b. isolating and preparing mammalian tissue for introduction to the support, and

c. introducing the mammalian tissue into the support, and

d. implanting the support containing mammalian tissue into a site within a patient.

22. The method of claim 21, wherein the site is selected from the liver, the natural pancreas, the renal subcapsular space, the mesentery, the omentum, a subcutaneous pocket, or the peritoneum.

23. The method of claim 21, wherein the support is further treated with at least one pharmaceutical compound that is selected from the group consisting of a growth factor, an anti-apoptotic compound, an anti-inflammatory compound, and an immunosuppressive compound.

24. A method of promoting vascularization in a patient, comprising the steps of:

a. incorporating at least one pharmaceutical agent capable of decreasing the degradation of HIF-1α

protein, and

b. isolating and preparing mammalian tissue for introduction to the support, and

c. introducing the mammalian tissue into the support, and

d. implanting the support containing mammalian tissue into a site within a patient.

25. The method of claim 24, wherein the site is selected from the liver, the natural pancreas, the renal subcapsular space, the mesentery, the omentum, a subcutaneous pocket, or the peritoneum.

26. The method of claim 24, wherein the support is further treated with at least one pharmaceutical compound that is selected from the group consisting of a growth factor, an anti-apoptotic compound, an anti-inflammatory compound, and an immunosuppressive compound.

27. A method of promoting vascularization in a patient, comprising the steps of:

a. incorporating at least one pharmaceutical agent capable of increasing cellular HIF-1α

protein levels, and

b. implanting the support into a site within a patient.

28. The method of claim 27, wherein the site is selected from the liver, the natural pancreas, the renal subcapsular space, the mesentery, the omentum, a subcutaneous pocket, or the peritoneum.

29. The method of claim 27, wherein the support is further treated with at least one pharmaceutical compound that is selected from the group consisting of a growth factor, an anti-apoptotic compound, an anti-inflammatory compound, and an immunosuppressive compound.

30. A method of promoting vascularization in a patient, comprising the steps of:

a. incorporating at least one pharmaceutical agent capable of decreasing the degradation of HIF-1α

protein, and

b. implanting the support into a site within a patient.

31. The method of claim 30, wherein the site is selected from the liver, the natural pancreas, the renal subcapsular space, the mesentery, the omentum, a subcutaneous pocket, or the peritoneum.

32. The method of claim 30, wherein the support is further treated with at least one pharmaceutical compound that is selected from the group consisting of a growth factor, an anti-apoptotic compound, an anti-inflammatory compound, and an immunosuppressive compound.